Great Point Partners LLC Has $26.60 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)

Great Point Partners LLC boosted its position in Evolus, Inc. (NASDAQ:EOLS) by 0.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,451,772 shares of the company’s stock after buying an additional 1,772 shares during the quarter. Evolus makes up about 5.1% of Great Point Partners LLC’s holdings, making the stock its 8th biggest position. Great Point Partners LLC owned about 3.92% of Evolus worth $26,602,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of EOLS. Perceptive Advisors LLC increased its stake in shares of Evolus by 166.8% in the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock worth $41,735,000 after purchasing an additional 2,477,623 shares during the period. Assenagon Asset Management S.A. increased its position in Evolus by 5,627.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock worth $10,276,000 after buying an additional 930,566 shares during the period. Lord Abbett & CO. LLC bought a new position in Evolus in the 1st quarter worth approximately $11,628,000. Zimmer Partners LP acquired a new position in shares of Evolus during the first quarter worth approximately $4,200,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Evolus by 84.2% in the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock valued at $5,683,000 after acquiring an additional 185,532 shares during the period. Institutional investors own 90.69% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on EOLS. Barclays boosted their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a report on Monday, September 16th. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, August 1st. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Friday, September 13th.

Evolus Trading Down 6.2 %

Shares of EOLS opened at $15.53 on Tuesday. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. The stock has a market cap of $972.18 million, a PE ratio of -14.79 and a beta of 1.31. Evolus, Inc. has a 1 year low of $7.44 and a 1 year high of $17.70. The stock has a 50 day simple moving average of $14.35 and a 200-day simple moving average of $13.12.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $66.91 million for the quarter, compared to analysts’ expectations of $65.06 million. On average, sell-side analysts predict that Evolus, Inc. will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling at Evolus

In other news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at $1,305,643.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.